{"id":"W2906996236","doi":"10.1182/blood-2018-99-116745","title":"Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Durvalumab; Medicine; Fludarabine; Cyclophosphamide; Internal medicine; Tolerability; Combination therapy; Refractory (planetary science); Immunotherapy; Oncology; Gastroenterology; Immunology; Pharmacology; Chemotherapy; Adverse effect; Cancer; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004819749,0.0003576575,0.001126744,0.0002571501,0.0001869834,0.0003837771,0.0003214963,0.000287568,0.0008510456],"category_scores_gemma":[0.0003462856,0.000153445,0.0004000583,0.0001897923,0.0001965318,0.0002118446,0.0001533562,0.0006425183,0.0001706066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004849454,"about_ca_system_score_gemma":0.0003903571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006128554,"about_ca_topic_score_gemma":0.002240682,"domain_scores_codex":[0.9998345,0.00007071924,0.00001376325,0.00002132757,0.0000267374,0.00003302409],"domain_scores_gemma":[0.9998174,0.0000412239,0.00003840306,0.0000159909,0.000009487701,0.00007743375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2495628,0.02147699,0.0475281,0.0007909027,0.002245967,0.001202704,0.0003458437,0.004238871,0.1527059,0.0002973474,0.002451423,0.5171531],"study_design_scores_gemma":[0.1291446,0.6046396,0.2042773,0.0001438163,0.002420638,0.002641694,0.0002132862,0.006571643,0.03826516,0.0002876807,0.01132946,0.00006505297],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996564,0.002232369,0.0001339498,0.00008770698,0.00002461348,0.0001156944,0.00008892867,0.00002305355,0.00072983],"genre_scores_gemma":[0.9983959,0.0006282018,0.0002725798,0.00006471529,0.00003646604,0.00006186676,0.0001490841,0.000003435917,0.0003877256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001126744,"threshold_uncertainty_score":0.003518522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01234072366315731,"score_gpt":0.2692520459626004,"score_spread":0.2569113222994431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}